The investigational oncolytic immunotherapy CG0070 produced an overall 30% complete response rate at 12 months for patients with high-risk BCG-unresponsive non-muscle-invasive bladder cancer.
The treatment method may delay need for systemic therapy in men with oligometastatic prostate cancer.
A new study examining gene expression assays for stratifying prostate cancer risk is suggesting that it may be possible to develop lower-cost alternatives and expand access.
“The high initial complete response rate and durability observed in the interim analysis is very promising and suggests that UGN-101 could be an effective and well-tolerated noninvasive treatment for patients with UTUC,” says researcher Seth Paul Lerner, MD.
Data from a recent study also indicate that overactive bladder patients discontinue pharmacotherapy long-term despite chronic symptoms.
Until now there has been no large, thorough investigation into the risk of clean intermittent catheterization in patients undergoing repeat injections of onabotulinumtoxinA.
General urologists are less likely to utilize third-line interventions for overactive bladder than those with additional female pelvic medicine and reconstructive surgery training.
Adding apalutamide prior to metastases may benefit men with prostate cancer who are no longer responding to androgen deprivation therapy, according to new phase III study findings.
Docetaxel (Taxotere) appears to help improve overall quality of life and delay time for subsequent therapy in men with both non-metastatic and metastatic prostate cancer, according to a new analysis of STAMPEDE trial results.
Despite a recent study’s promise, downsides to the procedure remain, according to one of the study’s authors.